System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Prof Delphine Staumont-Sallé is an expert in Dermatology at Centre Hospitalier Universitaire de Lille (France). As of October 2026, ScienceLeadR ranks Delphine Staumont-Sallé in the top 1% of experts worldwide for Dermatitis, Hypersensitivity and Skin Diseases, Genetic. Delphine Staumont-Sallé has authored 417 publications, the most recent in 2026, and is an investigator in 22 clinical trials, 8 of them ongoing. SLR score: 1,520 (community average: 125). How the SLR is computed.

LeadR Profile

Prof Delphine Staumont-Sallé Centre Hospitalier Universitaire de Lille France
1 520 ScienceLeadR Reputation 1520

Unlock

Register Login
Network Map

Dermatology

Subspecialties: Immunology - Pharmacy - Hematology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 2000 - 2026
Source: PubMed

Hôpital Claude Huriez

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 417

Citations

Citations: 4 165 1st author: 20 Last author: 87 Unique author: 8

Main journals

Ann Dermatol Venereol 117
Annales de dermatologie et de vénéréologie, FMC 38
Annales de Dermatologie et de Vénéréologie - FMC 36
J Eur Acad Dermatol Venereol 21
Br J Dermatol 15

Best Journals

Cell 2
Lancet 1
N Engl J Med 1

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Successful 15-step desensitization protocol for nivolumab and ipilimumab after a skin-test confirmed anaphylaxis to polysorbate 80: case report.
PMID 42631650 — skin, research design, hypersensitivity, melanoma, excipients, anaphylaxis, skin tests, polysorbates, nivolumab, therapeutics, ipilimumab		Melanoma Res20261
Clinical Phenotyping of Atopic Dermatitis Using Combined Global Severity (POEM) and Facial Burden (BoFA): A French Population-based Observational Study.
PMID 42573425 — dermatitis, eczema, phenotype, dermatology, dermatitis, atopic		Acta Derm Venereol20260
The spectrum of eosinophilic cellulitis (Wells' syndrome): new insights based on 114 cases.
PMID 42551694 — hypersensitivity, adrenal cortex hormones, cellulitis, eosinophils, therapeutics		J Allergy Clin Immunol Pract20260
Real-world Clinical Effectiveness of Guselkumab and Its Impact on Quality of Life and Sexual Quality of Life in Patients with Genital Psoriasis: Results from the CASSIOPEE Study.
PMID 42478139 — quality of life, syphilis, psoriasis, dermatology		Br J Dermatol20260
Answer to Elbaz et al.
PMID 42409350 — joint diseases		Joint Bone Spine20260

Clinical Studies 22

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 5

By phase:

N/A 7
Phase 3 6
Phase 2 5
Phase 4 3
Phase 2/Phase 3 1

By status:

Completed 8
Recruiting 6
Active not recruiting 3
Not yet recruiting 2
Terminated 1
Unknown 1
Withdrawn 1

By type:

Interventional 16
Observational 6

By Monocentric/Multicentric:

monocentric 7
multicentric2to4 1
multicentric5to9 0
multicentricup10 14

Main Topics

Ongoing Clinical Trials

8 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
A 52 week multi center randomized double blind placebo controlled basket study with an open label extension to investigate the efficacy safety and tolerability of remibrutinib (LOU064) in Chronic Inducible Urticaria (CINDU) in adults inadequately controlled by H1 antihistamines
2023-505739-12-01 — histamine antagonists, safety, urticaria, multiple chronic conditions, chronic inducible urticaria		Phase 3Active not recruiting2024
Long Term Safety and Efficacy evaluation of amlitelimab in participants of previous amlitelimab moderate to severe atopic dermatitis clinical trials
2023-506548-18-00 — safety, dermatitis, dermatitis, atopic		Phase 2/Phase 3Not yet recruiting2022
Effectiveness and Safety of Lebrikizumab Treatment in Adults and Adolescents with Moderate to Severe Atopic Dermatitis
2023-508235-31-00 — safety, dermatitis, signs and symptoms, adolescent, therapeutics, dermatitis, atopic		Phase 3Active not recruiting2024
Phase 3 Efficacy and Safety of Lebrikizumab in Adults With Nummular Eczema (LUMINE)
2025-522403-17-00 — safety, dermatitis, adrenal cortex hormones, eczema, therapeutics		Phase 3Recruiting2026
Platform study to evaluate the efficacy and safety of investigational compound(s) in patients with moderate to severe atopic dermatitis
2024-519081-49-00 — safety, dermatitis, respect, dermatitis, atopic		Phase 2Recruiting2025

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS